Same Class, Different Risk? Dapagliflozin versus Empagliflozin and Genitourinary Safety in Heart Failure with Preserved Ejection Fraction: A Retrospective Comparative Cohort Study
References
- ANKER SD., BUTLER J., FILIPPATOS G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.
- SOLOMON SD., MCMURRAY JJV., CLAGGETT B., et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–98.
- FRALICK M., MACFADDEN DR. A hypothesis for why sodium glucose co-transporter 2 inhibitors cause genital infection, but not urinary tract infection. Diabetes Obes Metab. 2020;22:755–8.
- KITTIPIBUL V., COX ZL., CHESDACHAI S., et al. Genitourinary tract infections in patients taking SGLT2 inhibitors. J Am Coll Cardiol. 2024;83:1568–78.
- RIAZ M., GUO J., SMITH SM., DIETRICH EA., WINCHESTER DE., PARK H. Comparative genitourinary safety of in-class sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction: a cohort study. Drug Saf. 2024;47:455–64.
- LJUNGBERG C., BONNESEN K., SCHMIDT M., et al. Empagliflozin versus dapagliflozin and urogenital adverse events in type 2 diabetes: a target trial emulation. Diabetes Obes Metab. 2026;28:7367–79.
- Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis. Eur J Heart Fail. 2026. [Author details and final pagination to be verified against the journal record before submission.]
- VON ELM E., ALTMAN DG., EGGER M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology statement: guidelines for reporting observational studies. Lancet. 2007;370:1453.
- KITTIPIBUL V., COX ZL., CHESDACHAI S., FIUZAT M., LINDENFELD J., MENTZ RJ. Genitourinary tract infections in patients taking SGLT2 inhibitors. J Am Coll Cardiol. 2024;83:1568–78.
- GEERLINGS S., FONSECA V., CASTRO-DIAZ D., LIST J., PARIKH S. Genital and urinary tract infections in diabetes: impact of pharmacologically induced glucosuria. Diabetes Res Clin Pract. 2014;103:373–81.
- PUCKRIN R., SALTIEL MP., REYNIER P., AZOULAY L., YU OHY., FILION KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503–14.
- KYRIACOU DN., LEWIS RJ. Confounding by indication in clinical research. JAMA. 2016;316:1818–9.
- KAUR R., KAUR R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgrad Med J. 2021;97:803–12.
- FOXMAN B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.
- PIESKE B., TSCHÖPE C., DE BOER RA., FRASER AG., ANKER SD., DONAL E., et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm. Eur Heart J. 2019;40:3297–317.
DOI: https://doi.org/10.2478/rjim-2026-0024 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749
Language: English, Romanian
Submitted on: Aug 18, 2026
Published on: Oct 26, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Razvan Alexandru Danau, Madalina Andreea Munteanu, Minerva Muraru, Camelia Nicolae, Gabriel Predoiu, Andreea Bardan, Viorel Jinga, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.